Alvotech (ALVO) Financials: Revenue & Earnings
ALVO$4.92-0.01 -0.30%
$1.76B
Market Cap
-8.31
P/E
21.36
Forward P/E
45
Score
Alvotech (ALVO) Financials: Revenue & Earnings
ALVO price $4.92 -0.01 -0.30%
- Ticker
- ALVO
- Price
- $4.92
- Change
- -0.01 -0.30%
- Market cap ?
- $1.76B
- P/E ?
- -8.31
- Forward P/E ?
- 21.36
- Dividend yield ?
- 0.00%
- Beta ?
- 0.18
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stocklytics score
- 45
- Value
- 43
- Quality
- 39
- Growth
- 52
Stocklytics score rationale: value 43, quality 39, growth 52.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 31918000 | 66616000 | 36772000 | 83029000 | 91434000 | 489682000 | 586321000 |
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of…
Earnings and financials
Alvotech (ALVO) trades at $4.92, with a market cap of $1.76B and a trailing P/E of -8.31. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 31918000 | 66616000 | 36772000 | 83029000 | 91434000 | 489682000 | 586321000 |
Insights · Dividends · Forecast · Financials · Learn